Trial Profile
Phase 3 Study of KHK7580 (A Long-term Study of KHK7580 in Subjects With Secondary Hyperparathyroidism Receiving Hemodialysis)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Evocalcet (Primary)
- Indications Secondary hyperparathyroidism
- Focus Adverse reactions; Registrational
- Sponsors Kyowa Hakko Kirin; Kyowa Kirin
- 02 Jul 2017 Status changed from recruiting to completed.
- 24 Sep 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
- 18 Sep 2015 New trial record